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ABSTRACT
BACKGROUND: Bordetella pertussis, otherwise known as whooping cough, is a highly
contagious respiratory disease that was once a significant source of childhood morbidity
and mortality. The availability and distribution of the pertussis vaccine beginning in the
1940s and onwards has helped to decrease transmission of infection, resulting in a major
decline in pertussis incidence among highly immunized countries over time. However,
there has been a reemergence of pertussis within highly immunized communities, with
rates progressively increasing over the last 30 years and an observed epidemiological shift
of higher incidence among adolescent and adult populations. Negative health outcomes in
pertussis infected children less than one year of age continue to remain a major public
health concern as intensity of symptoms and delay of recovery in this population often
leads to hospitalization and even death.
OBJECTIVES: This systematic review examines published literature in the last ten years to
provide an up-to-date analysis of the risk factors associated with the resurgence of
pertussis among highly immunized populations.
METHODS: A literature search was conducted using PUBMED and EBSCO databases using
combination searches with the key words pertussis, whooping cough, resurgence,
reemergence, recurrence, and comeback. Retrieved articles were refined based on the date
of publication and on the country in which the study was conducted. Only primary studies
with data collected between 2004-2014 from highly immunized countries with equal to or
greater than 90% of three doses of infant pertussis immunization coverage were included
in this review.
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RESULTS: Three main groups of risk factors contributing to pertussis reemergence were
identified among fourteen primary studies. The first category included four studies
assessing the risk factor of waning immunity. The second category comprised of six studies
focused on the risk factor of bacterial mutations. A third grouping of articles based on
immunization status and diagnosis recognition included one article associated with each of
the following risk factors: non-medical exemptions, inadequate childhood immunizations,
household transmission, and inadequate provider awareness.
CONCLUSION: Pertussis resurgence is a complex public health issue involving various
components and interrelated risk factors. Research into the associated waning immunity
through use of acellular vaccines and increased understanding of bacterial mutations
contributing to vaccine ineffectiveness will be important to improving current available
vaccines and should be a focus of continued efforts through collaboration among multiple
disciplines. Emphasis on the importance of up to date immunizations among the general
population and educational interventions directed toward health care providers and
patients will be key to reducing pertussis transmission in highly immunized countries until
new vaccines become available.
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BACKGROUND
1.1 Introduction
One of the top ten public health accomplishments in the twentieth century includes
the development of vaccines protecting populations against dangerous infectious diseases

(Centers for Disease Control and Prevention [CDC], 2013). The availability and
administration of vaccines has helped to control the transmission and incidence of specific
infectious diseases, which had once been significant sources of morbidity and mortality in
communities of all ages. Areas of high vaccination coverage, in which large percentages of
individuals were immunized, allowed for herd immunity to occur. Herd immunity is the
concept that unimmunized individuals within a population with high immunization rates
would be less likely to come into contact with individuals with the disease, thus decreasing
transmission rates. However, recently, there has been a recurrence of vaccine preventable
illnesses in areas where disease was once controlled due to high immunization coverage.
The reemergence of diseases, once well-controlled among highly immunized communities,
is becoming a significant public health issue. One example of this is the recurrence of
Bordetalla pertussis, otherwise known as whooping cough. Pertussis is a highly contagious
respiratory infectious disease that has made a comeback and is negatively affecting the
health of infants, children, and adults in highly immunized communities (Cherry, J.D., 2012;
Chiappini, E., Stival, A., Galli, L., Martino, M., 2013). The purpose of this systematic review is
to examine recent literature published in the last ten years regarding risk factors
associated with pertussis resurgence among highly immunized populations.
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1.2 Pertussis Pathophysiology/ Symptoms
Pertussis is a respiratory disease caused by the gram–negative bacteria Bordetella
pertussis in which humans are the only reservoir (World Health Organization [WHO],
2014). Transmission occurs through the spread of respiratory droplets among individuals
(Dworkin, M.S., 2005). When a person breathes in the pertussis bacteria, the method of
infection involves attachment of the bacteria to the cilia in the upper respiratory tract
causing inflammation and swelling (CDC, 2013). Symptoms of pertussis can start off like
the common cold but can progress into more serious coughing fits that last anywhere from
2-10 weeks. Pertussis progression may also lead to death in some individuals, often due to
decreased oxygen due to prolonged and frequent coughing.
The clinical course of pertussis disease is divided into three stages: catarrhal,
paroxysmal, and convalescent stages. During the catarrhal stage, possible symptoms
include mild intermittent cough and low-grade fever. This stage can last anywhere from 421 days though 7-10 days is the average period. Individuals and health care providers may
associate these symptoms with the common cold during this time, leaving many patients
misdiagnosed (Dworkin, M.S., 2005). As the cough becomes more severe, the paroxysmal
stage occurs and is defined by the paroxysmal type coughs. These coughs occur
simultaneously and rapidly in efforts for the body to rid the lungs of thick mucous which
has developed. Another symptom in this stage is the “whoop” sounds, which may occur at
the end of each paroxysmal cough. Paroxysmal attacks occur at an average of 15 attacks per
24 hours, often causing vomiting and extreme fatigue. The usual time period for the
paroxysmal stage is 1-6 weeks but may last anywhere up to 10 weeks. (CDC, 2013)
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The last stage of pertussis disease is the convalescent stage and is characterized by a
recovery time period with decreased frequency of paroxysmal coughs. The usual time
period for this stage is 7-10 days, with a range of 4-21 days (CDC, 2013).

1.3 Complications of Disease
Infants below the age of one year old are at highest risk for developing the
complications of pertussis. Approximately 50% of infants diagnosed with pertussis are
hospitalized (CDC, 2013). Additional statistics from the CDC state that among infants who
are hospitalized:

● 1 in 4 (23%) get pneumonia (lung infection)
● 1 or 2 in 100 (1.6%) will have convulsions (violent, uncontrolled shaking)
● Two-thirds (67%) will have apnea (slowed or stopped breathing)
● 1 in 300 (0.4%) will have encephalopathy (disease of the brain)
● 1 or 2 in 100 (1.6%) will die
Though milder symptoms are often seen in adolescents and adults who contract pertussis,
complications from the cough can cause weight loss (33%), loss of bladder control (28%),
passing out (6%), and rib fractures from severe coughing (4%). Less than 5% of teens and
adults with pertussis are hospitalized (2013).
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1.4 Diagnosis of Pertussis
Pertussis can be diagnosed through several laboratory tests including culture,
polymerase chain reaction (PCR), and serology. The CDC (2013) defines culture as the gold
standard to diagnosing pertussis due to its high specificity and its ability to identify specific
strains and antimicrobial resistance. As a result, it is the preferred diagnosis method during
outbreaks. Culture is obtained through nasopharyngeal aspirates or swabs.
Polymerase chain reaction (PCR) is another lab test used for pertussis diagnosis in
patients, though it is often difficult to obtain from infants (Sintchenko, 2008). PCR tests
allow for rapid results; however the high sensitivity of the assay may also produce more
false-positive test results (CDC, 2013). Guiso (2014) addresses this topic of high sensitivity
versus high specificity of lab tests in the adolescent and adult population arguing that the
higher false-positive rates with PCR may lead to misdiagnosis, though providing the benefit
of attaining quicker results for this age group (p. S121).
Serological blood test is another diagnostic test available and often beneficial in
examining pertussis. Sintchencko (2008) states, “the greatest specificity for the serological
diagnosis of B. pertussis infection is achieved by the measurement of IgG and IgA
antibodies against pertussis toxin”(p.143). According to Bamberger, E.S. & Srugo, I. (2008),
this test is often ineffective for infants with limited “measurable antibodies” though useful
in older adults who have negative PCR and culture results after a prolonged course of
whooping cough (p. 136).
The varying methods of diagnosis at different stages of symptom presentation can
make acquisition of consistent measures of disease occurrence difficult. Guiso (2014)
discusses the importance of formulating a standardized method for biological diagnosis of
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pertussis in order to gain a more accurate perspective of pertussis incidence and
prevalence rates. This is especially important in addressing the actual burden of disease
occurring in immunized populations and in determining future expectation of outbreak
occurrence.

1.5 Treatment
Different types of antibiotics for treatment of pertussis are available and are most
effective if initiated earlier during the course of infection. Schaffner (2006) describes the
challenges of how delayed diagnosis of pertussis may lead to suboptimal disease outcome,
where antibiotic use may help symptoms yet do not “alter the course of the disease” (p. 29).
This is because the exposure to the bacteria has already caused damage to the lining of the
respiratory tract, and “treatment after three weeks of illness is unlikely to help because the
bacteria are gone from your body though symptoms are still there” (CDC, 2013). However,
the identification of infected persons would allow prophylactic treatment to be distributed
to those who are in close contact with the infected individuals, thus helping to decrease the
spread of the disease and severity of symptoms in those diagnosed in early stages of the
disease (Schaffner, 2006). According to Bamberger & Scrugo (2008), the prophylactic
recommendations in the Academy of Pediatrics Red Book instruct “Chemoprophylaxis to be
administered to all household contacts and other close contacts, regardless of age and
immunization status” (p. 136).
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1.6 Whole Cell Pertussis Vaccine (wP)
Until the pertussis vaccine was introduced and dispersed among populations
through public health efforts, pertussis was one of the main causes of childhood mortality
in developed countries (Boven, M., Ferfuson, N.M. &Rie, A., 2004). In the 1940s the whole
cell pertussis vaccine consisted of inactivated suspensions of the whole Bordetella
pertussis bacteria (WHO, 2013). The pertussis vaccine was approved for routine use by the
American Academy of Pediatrics in 1943, and in 1944 the American Medical Association
recommended its use. (CDC, 2013; Shapiro–Shapin, 2010). Halperin, S.A. (2007) describes
the benefits of the whole cell pertussis vaccine provision to communities in the 1940s and
its effectiveness in reducing pertussis rates to its lowest in the U.S. until the 1980’s (p.111).
Statistics from the Centers of Disease Control describe the effect of vaccines on disease
incidence by stating: “In 1934 the whooping cough incidence in the U.S. was 209
cases/100,000 residents, and the death rate was 5.9/100,000, yet by 1948, routine use of
the vaccine reduced the incidence to 51 cases/100,ppp and death rate to <1/100,000. After
1960 incidence was 10 cases/100,000” (2013).
In regards to the use of whole cell pertussis vaccine outside the U.S., the World
Health Organizations (WHO) indicates, “whole cell pertussis vaccine were first

formulated in 1963 and revised and incorporated into recommendations for DTP in
1978. In 1989 the recommendations for the combined vaccine were revised and
most recent revised recommendations for whole cell pertussis vaccines were
adopted by the ECBS in 2005” (WHO, 2013).
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1.7 Acellular Pertussis Vaccine (aP)
In efforts to limit negative vaccine side effects of the whole cell pertussis vaccine,
acellular pertussis vaccines were introduced in 1991 as booster shots and as
immunizations for primary vaccination in 1997 (Zhang, 2008). Acelluar vaccines were
made up of components of purified, detoxified B. pertussis antigens (WHO, 2014). Use of
these acellular vaccines versus whole cell vaccines helped to protect individuals from
disease while decreasing side effects of redness and swelling that were often associated
with whole cell pertussis vaccine administration (Zhang, 2008). Pertussis vaccinations
were administered in a series of shots to maintain immunity. The number of doses
recommended varied by country though most schedules included at least 3 doses of
pertussis vaccine to be given before six months of age in infants (Tan, Trindade &
Skowronski, 2005). In the U.S., a complete pertussis immunization schedule for children
included a series of five immunizations, with the final dose given between 4-5 years old
(CDC, 2013). However, with the reemergence of pertussis in highly immunized populations,
an adolescent booster dose of the acellular pertussis vaccine became available and also
recommended. In May 2005, the FDA approved Tdap, a tetanus and diphtheria booster
immunization that also included an acellular pertussis booster component. The Tdap
immunization was first approved as a booster dose for ages 10-18 years in May 2005 and
then as the first pertussis booster vaccine in adults ages 11-64 years in June 2005
(Dworkin, M.S., 2005). Whole cell vaccines were completely stopped from use in the U.S. in
2001 (Witt, M.A., Arias,L., Katz, P.H., Truong, E.T., & Witt, D.J., 2013), although it is still
commonly used in developing countries due to the decreased cost of vaccine (WHO, 2014).
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1.8 Burden of Disease
The burden of pertussis disease has shown significant impact on both developing
and developed nations. Estimates by the World Health Organization (WHO) state that in
2008, “16 million cases of pertussis occurred worldwide, 95% of which were in developing
countries, and that about 195, 000 children died from the disease” (2011). Another
source’s findings describe global pertussis rates as attributing to 50 million cases and
300,000 deaths every year (He, 2008). Many of these developing nations are underimmunized for pertussis due to low socioeconomic conditions such as poverty and lack of
quality healthcare structures. The Global Vaccine Action Plan (GVAP) started by the World
Health Organization aims to increase vaccination rates in countries with low immunization
coverage. According to the World Health Organization, the GVAP was developed to provide
a framework of goals for prevention of vaccine preventable diseases globally (2014). The
GVAP 2011-2020 defines a vaccine goal that “by 2020, coverage of target populations
should reach at least 90% national vaccination coverage and at least 80% vaccination
coverage in every district or equivalent administrative unit for all vaccines in national
immunization programmes” (WHO, 2014). A study by Jackson and Rohani (2012), which
assessed the global burden of pertussis disease in the last twenty years, concluded that
developing countries continue to have high mortality and morbidity rates due to pertussis
while specific developed countries with high immunization rates continue to experience
resurgence in whooping cough (p. 2). Though Jackson and Rohani’s results showed that a
“mix of increasing, stationary, and decreasing trends in high-coverage countries” (p. 2) and
a “lack of consistent geographical pattern in the trends” (p.3), increased incidence rates
were reported in the 1980s for high vaccine coverage countries such as the U.S., Israel,
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Australia, and Poland (p. 2). Challenges in regards to comparing rates of pertussis among
highly immunized nations involve differences in vaccine schedules and variations in
vaccine and disease tracking. Clark, T. A., Messonnier, N.E., & Hadler, S.C. (2012) states,
“Differences in vaccination programs and surveillance systems limit the direct comparison
of pertussis burden among countries” (p. 211). Researchers also attribute challenges due to
variations in immunization coverage which impacts how the epidemiology of pertussis in
the nation is interpreted (Wood, N & McIntyre, (2008), p.202). In the U.S., the CDC reported
48,277 cases in 2011, with increased disease incidence seen among 7- 10 year olds in 2010
and among 13-14 year olds in 2012 (2014). Many more pertussis cases in highly
immunized populations may be undiagnosed. Infants continue to remain the most
vulnerable population being affected by pertussis reemergence, as hospitalization and
death often occur in this age group due to challenges in recovery (CDC, 2014).

1.9 Epidemiological Shift
A resurgence of pertussis disease began to emerge in highly immunized countries,
such as in the U.S. in 1982 with peaks in 2005, 2010, and 2012 (Cherry, 2012). Halperin
(2007) discusses the epidemiological shift seen in many highly immunized countries from
increased cases seen in infants and children to adolescents and adults (p. 111). Leung,
A.K.C. & Robson, W.L.M. (2007) describes this shift stating, “in recent years, almost 50% of
reported cases occurred in individuals older than 10 y of age; the greatest increase has
been noted in individuals 10 to 19 y of age” (Leung, A.K.C. & Robson, W. L.M., (2007), p.
355). Though pertussis in many adolescents and adults may present as mild illnesses and
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even go unnoticed, the exposure of infants to these infected individuals may result in
pertussis transmission in which severe illness and death can occur (Leung, A.K.C. et al.
(2007) p. 354). Abuhammour (2008) further relates the increased infection rates of infants
to possible exposure through contact with adolescents and adults. Dworkin, M.S. (2005)
stresses the importance of identifying cases of pertussis in adolescents and adults to help
stop the cycle of transmission to infants (p. 44).
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METHODS
2.1 Literature Search Strategy
A literature search on January 17, 2014, was conducted using PUBMED AND EBSCO
databases with key word phrase searches including the terms “pertussis and reemergence”,
pertussis and recurrence”, “pertussis and comeback”, “pertussis and resurgence,
“whooping cough and re-emergence”, “whooping cough and recurrence”, “whopping cough
and comeback” and “whooping cough and resurgence”. Restrictions were placed on journal
articles published within the last ten years and to research written in English. A second
search was conducted on March 11, 2014 using the same key word phrases to verify
inclusion of all pertaining articles. All primary articles that included data on risk factors
associated with the resurgence of pertussis from 2004-2014 were included in this review.

2.2 Primary Outcome
All primary studies that assessed risk factors in association with pertussis infection
as the primary outcome between 2004-2014 were included in this systematic review.

2.3 Inclusion Criteria

▪ Studies from countries with greater than or equal to 90% infant vaccine coverage
for the third dose of pertussis vaccine specific to the year(s) in which the study was
conducted
▪

Primary articles looking specifically at risk factor association and using data from
human studies
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▪

Studies published within the years 2004-2014 in which all data or part of the data
was collected between 2004-2014

2.4 Exclusion Criteria (see Figure 1 and Table 1)

▪ Studies in which pertussis was not the main focus of the article
▪ Research printed in a language other than English
▪ Studies that were not primary studies identifying risk factor association to pertussis
infection (includes review articles, descriptive articles, surveillance articles, case
reports, intervention studies)

▪ Research conducted in countries exhibiting low immunization coverage, less than
90% of infant vaccine coverage for three doses or pertussis vaccine between 20042014
▪

Studies involving animal models or mathematical models

▪

Research containing data retrieved before 2004

2.5 Data Collection
Articles were organized into tables (see Tables 2-4), defining highly immunized
countries where each study took place, study design, the researchers’ end point being
pursued from the article, risk factor identified, and results of the article. After identifying a
list of articles from the initial search with use of various keywords, abstracts were
reviewed and exclusion of articles that were non-English and articles in which pertussis
was not the main focus were excluded from the review. Data analysis continued as full
articles were reviewed and exclusion of non-primary study articles regarding pertussis was
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initiated. Animal models, mathematical models, and studies with data from countries of low
immunization coverage or with data collected prior to 2004 were also excluded from the
review. A final list of fourteen primary studies were reviewed and then grouped together
based on category of risk factor identified by the authors. The two largest categories of risk
factors in which common article themes were found included the risk factor of waning
immunity and bacterial changes. Four articles were grouped in the waning immunity list,
while six articles were grouped in the bacterial changes list. A third category of articles was
created based on one unifying article that included each of the following risk factors: nonmedical exemptions, inadequate childhood immunization, inadequate provider awareness,
and household transmission.
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Figure 1: Flow Diagram of Literature Search

148 Articles
initial search
PubMed
and EBSCO

39 Articles
(Pertussis not main
focus, Non-English
articles)

109 Articles
PubMed and EBSCO

68 Articles
(Group meetings,
review, descriptive,
surveillance, and nonprimary study articles)

43 Articles
PubMed and EBSCO

29 Articles
(Intervention studies,
Non-human models, low
immunization country,
case reports, data
outdated)

14 Articles
included in final review
PubMed and EBSCO
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Table 1: Excluded Articles
Reason for Exclusion
Non-primary study articles
(review articles and descriptive articles defining pertussis, diagnosis,
lab reporting, symptoms)
Topic (articles where pertussis is not main topic)
Non-English
Vaccine (history, description, developments, side effects)
Intervention articles
Surveillance
Countries with low immunization coverage
Immunity (not primary studies)
Animal models
Mathematical models
Case reports
Group meetings regarding pertussis
Data outdated (collected prior to 2004)
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Number of
Articles
43

22
17
15
12
8
7
7
6
3
3
3
2

Table 2: Waning Immunity
Author/
Year

Country

Type of
Study

Endpoint

Risk Factor
Identified

Results

Witt, M.A.,
Arias, L., Katz,
P.H., Truong,
E.T. & Witt,
D.J.
(2013)

U.S.

Observational
Study

Immunity

Use of acellular
vaccines

Use of a complete
acellular vaccine
series is less
effective than one or
more doses of whole
cell pertussis
vaccine (RR= 8.57)

Smits et al.
(2014)

Belgium

Observational
Study

Immunity

Use of acellular
vaccines

Use of wP induces
longer lasting
immunity than aP

Trollfors, B.,
Dotevall, L.,
Sundh, V
&WelinderOlsson, C.
(2011)

Sweden

Observational
Study

Immunity

Use of infant
vaccine series
only without
more booster
doses

Booster pertussis
doses needed,
number of booster
doses and timing of
doses for effective
immunity still
unknown

Han, W.G.H.
et al.
(2013)

Netherlands

Observational
Study

Immunity

Limited
immunological
memory

Long-term
immunity after
infection is often
lost in older age
groups
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Table 3: Bacterial Changes

Author/
Year

Country

Type of
Study

Endpoint

Risk Factor
Identified

Results

Pawloski, L.C. et
al. (2014)

U.S.

Observational
Study
(Screening of
13000 isolates
from outbreak
and surveillance
studies)

Bacterial mutations

Pertactin-deficient B.
Pertussis Strains

Recent dramatic increase
in pertactin-deficient B.
pertussis isolates
throughout the U.S.

Gent, M.V.,
Bart,,M.J, Han, G.J.,
Hedie, V.D.,
Heuvelman, K.J., &
Mooi FR.R., (2012)

Netherlands

Observational
Study

Bacterial mutations

Pathogen
Mutations/Adaptation

Small mutations can drive
large changes of bacterial
pathogen and may cause
resistance to vaccination

Kallonen,T. et al.
(2011)

Finland
Poland
Serbia
UK

Observational
Study

Bacterial mutations

Bacterial mutations

Possible vaccine-driven
differences in genomic
content between old and
recent vaccine strains
among 4 different
countries

King, A.J. et al.
(2008)

Netherlands

Observational
Study

Bacterial mutations

Bacterial mutations

Emergence of ptxP3
strains through bacterial
adaptation causing
divergence between
vaccine and circulating
strains.

Shuel, M. et al.
(2013)

Canada

Observational
Study

Bacterial strain
domininace

Dominance of
pertussis strain

One predominant B.
pertussis clone in Ontario,
Canada identical to strains
involved in epidemics in
Europe and Australia

Abu Raya B et al.
(2012)

Israel

Observational
Study
(2 years)

Bacterial strain
dominance

Predominance of
strains

Circulating strains in Israel
during high incidence rate
years are similar to strains
found in Europe
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Table 4: Inadequate Immunization Coverage/ Provider Awareness

Author/Year

Country

Type of
Study

Endpoint

Risk
Factor
Identified

Results

Atwell, J.E.(2013)

U.S.

Observational
Study

Infection Route

Non-Medical
Exemptions
(NMEs)

NMEs: source of
pertussis outbreak in
California 2010

CDC, MMWR
(2013)

U.S.

Survey

Immunization
coverage

Inadequate
Childhood
immunization

Low SES and poverty
may be contributing
factors to inadequate
childhood immunization
dispersed across the U.S.

Kwon, H.J., Yum,
S.K., Choi, U.Y., Lee,
S.Y., Kim,J.H,
&Kang,J.H.(2012)

South Korea

Observational
Study

Infection
Route/
Immunization
Coverage

Household
Transmission

Household
transmission/
inadequate infant
immunization

Abuhammour, W.
(2007)

U.S.

Survey

Diagnosis

Inadequate
provider
knowledge

Misdiagnosis of pertussis
patients leads to
ineffective infection
detection and control
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RESULTS
3.1 Waning Immunity

In this review, four studies were identified that focused on waning immunity as a
risk factor associated with pertussis re-emergence. Witt, M.A., Arias, L., Katz, P.H., Truong,
E.T. & Witt, D.J.(2013) looked at the association of pertussis incidence with the type of
pertussis vaccination received, assessing whether receiving whole cell pertussis (wP)
vaccine at any point showed a lower risk of pertussis infection versus those who had
received only acellular pertussis (aP) vaccines. Access to Kaiser Permanente’s (KP)
electronic medical records allowed researchers to examine lab confirmed pertussis results
and vaccine histories for 263,496 patients ages 8-20 years old born between 1990-2001.
904 cases of pertussis were found among these patients. Results showed an increased risk
of pertussis cases being highest in those who received 5 doses only of aP vaccine for both
groups (RR= 8.75, P<.0001) when compared to patient histories who received at least one
dose of wP. Members who received all 6 doses of aP had a 3.55 relative risk of pertussis (P<
.0001) when compared to those with at least one dose of wP. Though a decreased risk of
pertussis was seen in patients who received 6 doses versus five doses of only aP vaccine,
this group still exhibited a high relative risk for pertussis infection when compared to those
who had one or more doses of wP vaccine. The authors concluded that use of only acellular
vaccines in a vaccination series of 5 doses provides a shorter immunity span than when
one or more immunizations of whole cell vaccines are included in an immunization series.
The authors also concluded that patients who received a sixth booster dose of acellular
vaccine in a series of aP vaccine exhibited a longer lasting immunity against pertussis.
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Smits et al (2014) assessed a cohort of 24 Belgian preadolescents with a median age
of 10.1 years old. Through collected blood samples, indications of residual T cell memory
were evaluated. Participants included those who received a pertussis vaccine from infancy
through the last pertussis booster shot. The last booster shot was given at a median
interval of 4.8 years for wP vaccinated children and at a median interval of 2.7 years for aP
vaccinated children (p=0.004) from the last pertussis vaccine. Eleven adolescents had
received wP in infancy and 13 adolescents had received aP in infancy. All 24 participants
received aP as their last pertussis booster dose. Results showed that individuals who
received the wP pertussis immunization in infancy had longer lasting immunity than those
individuals who were vaccinated with aP as infants.
The study by Trollfors, B., Dotevall, L., Sundh, V &Welinder-Olsson, C. (2011)
involved outcome assessment of a mass vaccination project in Gothenburg, Sweden held
between 1995-1999 from infants to 10 years of age. Pertussis incidence was assessed
between 1999-2009 through PCR and culture verified lab cases and hospitalizations.
Among 1,973 cases identified, 450 cases were from patients who had received 3 doses of a
monocomponent pertussis vaccine with highest incidence seen in infants below the age of
12 months of age. A recurrence of pertussis infection was seen in 1999 with a peak in 2004,
marking an outbreak of the disease. However, disease incidence decreased again after 2004
when booster doses began to be recommended for children 10 years of age from 20052006 and for children 5-6 years of age from 2007 onwards. Study outcomes revealed a
shorter span of immunity in pertussis vaccinations with improvement in immunity
occurring when booster doses were given.
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Finally, a study by Han et al (2013) conducted in the Netherlands analyzed blood
samples for 62 pertussis patients at various time periods after infection. The age range was
between 9.4-78.9 years with a median age of 37.5 years. Samples were placed in groups of
< 30 years old, > or equal to 30 years old, < 3 months after diagnosis, and > or equal to 3
months after diagnosis. The blood sample analysis involved B. pertussis-specific (memory)
CD4+ T cell activity at the epitope-level at different time periods after pertussis diagnosis.
The authors state, “ long-lived Th1 CD4+T cells are essential for protective immunity
against pertussis.” (p.1). Results showed a decrease in these memory cells among the older
age group of this study who were previously infected. One conclusion by the researchers
state, “Loss of multi-epitope specificity in memory pertussis CD4+ T cell responses could
play a role in waning effectiveness of pertussis immunity in older age groups. These
observations can have implications for vaccination strategies and vaccine development” (p.
5). The authors concluded a loss of long- term immunity occurs after infection in older age
groups and recommended use of this knowledge of “limited immunological memory to B.
pertussis” in future research towards novel vaccine development (p. 1, 5).

3.2 Pertussis Bacterial Strain Changes
Six studies in this systematic review involved analysis of pertussis bacteria strains
to determine changes in the structure of the bacteria over time, while discussing the
association of pertussis resurgence to mutation and adaptation of bacterial strains causing
resistance against vaccines. An Australian study by King et al. (2008) identified pertussis
bacterial strains with genetic changes in which the absence of 98 genes were found in “at
least one of the b. pertussis strains tested” among 43 Dutch isolates between 1993-2004
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(p.1). The authors discuss emergence of ptxP3 strains through bacterial adaptation causing
“divergence between vaccine and circulating strains” and pertussis resurgence.
In another study by Kallonen et al. (2011), researchers examined old pertussis
isolates (1941-1984) and more recent isolates (1996-2004) from Finland, Poland, Serbia,
and the UK and identified genomic differences among the pertussis strains compared
(p.2041, 2011). Since the reference bacterial strain Tohama I was used for production of
both whole cell and acellular pertussis vaccines, strain resistance to pertussis vaccinations
is highlighted due to changes in the bacterial genetic material over time (p. 2041).
In the study conducted by Pawloski et al. (2014), researchers looked at 1,300
pertussis isolates dated from 1935- 2009 in the U.S. and identified 306 isolates lacking
pertactin (p. 119). These results show a link to the possible ineffectiveness of the acellular
vaccine since pertactin is a significant antigen component in the acellular pertussis vaccine.
The study conducted by Gent, M.V., Bart, M.J, Han, G.J., Hedie, V.D., Heuvelman, K.J., &
Mooi FR.R., (2012) assessed 704 Dutch pertussis strains between 1949-2010 also showed
genetic mutations in pertussis bacteria. The authors concluded that even small genetic
changes over time can produce unique pertussis bacterial strains. Increases in pertussis
outbreaks could thus be attributed to unique pertussis bacterial strains emerging in
resistance to vaccines.
In support of this notion, two studies identified similarity of strains found during
outbreak seasons to that in other highly immunized countries. A Canadian study in 2013
examining 521 pertussis isolates from 1998-2006 showed similarities to pertussis isolates
during epidemics in Europe and Australia, suggesting one predominant clone of pertussis
bacteria having emerged and is related to the pertussis resurgence (Shuel et al. 2013).
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Research conducted on pertussis strains in Israel between 2007-2008 identified a
predominance of specific pertussis strains correlating to the most common European
pertussis strain between 1999-2004 (Abu Raya B et al. 2012). These similarities in
outbreak strains may signify an emergence of dominant pertussis strains correlating with
pertussis mutations which differ from vaccine strains, thus leading to “increased pertussis
activity” (p.762).

3.3 Non-Medical Exemptions
Lower rates of childhood immunization, either through higher frequency of nonmedical exemptions or lower socioeconomic levels, were also identified as a risk factor for
the resurgence of pertussis. A California study initiated after a major pertussis outbreak in
2010 identified unimmunized children through non-medical exemptions (NME’s) as being
a primary route of transmission of pertussis in highly immunized communities (Atwell,
2010). Researchers concluded pertussis re-emergence stemmed from clusters of nonmedically exempted children experiencing pertussis infection and spreading it to other
individuals within the higher immunized communities.

3.4 Inadequate Child Pertussis Immunization Rates
The National Immunization Survey (NIS), initiated through the CDC, conducted a
random–digit-dialed telephone survey among households in the U.S. for children aged 1935 months (CDC, 2013). Results for children born during Jan 2009- May 2011 showed
82.3% pertussis immunization coverage for greater than or equal to 4 doses of Dtap
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which was actually below the Healthy People 2020 target percentage of 90% (p.733).
Other specific results from this study included inconsistencies of immunization rates across
the U.S. states and decreased pertussis immunization rates in families under poverty level
(CDC,2013). Researchers defined the significant risk of low immunization coverage as
“clusters of unvaccinated children leave communities vulnerable to outbreaks of disease”
(p. 739). This study revealed low immunization coverage in children across the U.S., often
correlating with low socioeconomic status, while exposing a possible route of pertussis
infection among children in the U.S.

3.5 Inadequate Provider Knowledge
One study identified inadequate provider knowledge of pertussis identification and
recurrence as a risk factor to the re-emergence of pertussis. Results of a 2007 health care
provider survey distributed to physicians in Michigan showed a “decreased awareness” of
the current need in identifying and diagnosing pertussis in adolescent and adult
populations (Abuhammour, 2008). The survey included a case study to be reviewed by
physicians with pertaining questions that followed. Results indicated a decreased
identification of pertussis as a “differential diagnosis of adults with respiratory tract
illness” (p. 44). Inadequate provider awareness of the importance in considering pertussis
as a differential diagnosis in patients could lead to misdiagnosis and decreased
identification and treatment of patients with pertussis, leading to increased risk of
exposure to individuals in close contact with these infected persons.
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3.6 Household Transmission
A prospective multicenter study conducted in South Korea recognized household
transmission of pertussis among family members as the main route of transmission for
infants below the age of six months (Kwon, H.J., Yum, S.K., Choi, U.Y., Lee, S.Y., Kim, J.H. &
Kang, J.H., (2012) p.2). The authors indicate 85.7% of infant transmission was associated
with contact from an infected parent though they did not specify the immunization status
of the parent. In this cohort, all but one of the twenty-one infants showed an incomplete
pertussis vaccination history. As infants less than the age of one are at highest risk for
experiencing symptoms of pertussis that may lead to morbidity and/or mortality, this
study shows the significance of ensuring infants receive the complete pertussis vaccination
series and that parents and caretakers are up to date on booster pertussis vaccinations as
being essential to decreasing infant pertussis transmission.

DISCUSSION
Public health efforts towards reducing pertussis transmission in communities with
high immunization rates lie not only in keeping vaccination rates high, but also in
addressing risk factors that are unique to pertussis transmission in highly vaccinated
populations. Waning immunity through decreased efficacy of acellular vaccines and vaccine
ineffectiveness due to genetic changes in pertussis bacteria are two main points addressed
in this review. The promotion of immunization and educational interventions along with
future research toward new vaccine development is essential in addressing the resurgence
of pertussis in highly immunized populations.
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4.1 Waning Effectiveness of Immunizations
Two studies point towards the recent use of the acellular vaccines versus whole cell
vaccines as a contributor to pertussis comeback due to decreased long-term effectiveness
of immunization series that contain only acellular vaccines (Smits et al. 2014; Witt et al.
2013). A study in Belgium evaluated T cell responses in preadolescents who had been
vaccinated and identified longer lasting immunity in those with whole cell vaccinations
(Smits et al. 2014). After a thorough evaluation of electronic medical records, Witt et al.
(2013) correlated an increase in pertussis cases among individuals with acellular
vaccination versus those who received at least one dose of whole-cell pertussis vaccine in
the U.S. state of California. Both studies discussed the long-term effectiveness seen in whole
cell pertussis immunization series versus acellular pertussis immunization series. These
studies point to the idea that the shift to acellular vaccines from whole cell vaccines may be
a driving factor contributing to the pertussis reemergence. Since acellular vaccines began
replacing whole cell vaccines as booster shots in 1991, as primary immunizations in 1997,
and completely in 2001, one hypothesis posited through these studies is that the use of
acellular vaccines may contribute to the waning immunity observed in countries such as
the U.S. and underlie the pertussis outbreaks among highly immunized communities.

4.2 Bacterial Changes Leading to Vaccine Ineffectiveness
Bacterial mutations and specific genomic variations of new pertussis strains may
affect vaccine effectiveness as current pertussis vaccines were once developed to target
older pertussis bacterial strains. Of the six articles identifying changes in bacterial strains
of pertussis as being associated with whooping cough re-emergence, four articles discussed
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genetic mutations and differences in new pertussis bacteria strains (Gent, M.V., 2012; King
et al., 2008; Pawloski, L.C. et al. 2014; King et al. 2008). Pawoloski’s study identifying
pertactin deficient pertussis bacteria provides insight into the ineffectiveness of long-term
immunity with acellular vaccines due to bacterial mutation, as pertactin is an important
component of the acellular pertussis vaccine (2014). A study by van Gent, M.V (2012)
concluded that small genetic mutations within a time span of 6 to 19 years may cause
resistance to vaccination, confirming the idea of bacterial mutations affecting efficacy of
current vaccines. The study from Australia by King et al. (2008) also describes bacterial
adaptation and pertussis emergence that can recur through divergence between changed
circulating bacterial strains and vaccines. The study consisting of data from Finland,
Poland, Serbia, and the UK describe these bacteria changes noting clear differences in the
structure of old circulating pertussis bacteria versus newer strains (Kallonen et al. 2011).
Two studies in Canada and Israel each point towards a dominant pertussis strain having
emerged and showing identity to pertussis bacterial strains from outbreaks across Europe
(Shuel, M. et al. (2013); Abu Raya B et al. 2012). These results tie into the theory of new
pertussis strains with increased fitness emerging across the world, thus causing decreased
vaccine effectiveness of currently available pertussis vaccines.

4.3 Immunization Interventions
Promotion of immunization programs to all age groups as a prevention intervention
can greatly help control pertussis outbreaks. Until a novel vaccine is approved for
distribution, pertussis vaccination among children, adolescents, and adults is an important
aspect to pertussis prevention. The importance of initiating quality immunization
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intervention strategies to children, adolescents, and adults is to help ensure completion of
childhood pertussis immunization series while preventing the transmission of pertussis
from adolescents and adults to infants. The National Immunization Survey (NIS), initiated
through the CDC, concluded that vaccination rates vary across states in the U.S. and groups
of unvaccinated children often live under poverty level (2011). These unvaccinated
children could be the source of transmission of whooping cough. Continued promotion of
immunization programs in underserved areas may help decrease rates of unvaccinated
children while helping maintain comparable rates of immunization across the U.S. and
other highly immunized countries.
As the current epidemiological shift of pertussis rates show a larger percentage of
confirmed pertussis cases in adolescents and adults, vaccination efforts to confirm and
promote booster pertussis immunizations in adolescents and adults can help decrease
disease transmission to infants. A study by Trollfors, B., Dotevall, L., Sundh, V & WelinderOlsson, C.(2011) stresses the need for booster doses in children and adolescents as the
study revealed how pertussis incidence can reoccur in children who only received infant
pertussis doses versus those who received a booster vaccine in adolescence. The study by
Han et al. (2013) showed how booster doses for adults is a significant component of
pertussis prevention due to decreased T cell memory responses in older age groups who
had previously been infected with pertussis. Immunization programs, focusing on
immunizing parents and household members can also help with pertussis prevention. The
study by Kwon, H.J. et al. (2012) revealed a large percentage of infant pertussis
transmission occurring through household contacts may benefit from cocooning
immunization intervention strategies. Cocooning is a method of immunizing healthcare
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providers and family members who come in constant contact with newborns. Cherry
(2012) encourages cocooning, immunizing pregnant women and promoting earlier
immunization series for infants as a way of helping to decrease pertussis transmission in
infants (p. 787).

4.4 Patient Education
One article in this review discussed unvaccinated children being a risk factor
associated with the resurgence of pertussis and recent outbreaks in the U.S. Researchers
associated the clusters of non-medical exempted children from attaining pertussis
vaccinations with the 2010 outbreak of pertussis in California (Atwell, 2010). This
outbreak resulted in >9000 cases, 809 hospitalizations, and 10 infant deaths. (Winter et al.
2012). Educating parents on the need of initiating and completing the pertussis
immunization series in children and the benefits versus risks/side effects of vaccination
can help decrease transmission of the disease from those who are not fully immunized to
the communities in which they reside.

4.5 Provider Education
Educating health care providers on the importance of recognizing pertussis as a
diagnosis for respiratory symptoms in adolescents and adults will also help decrease
transmission of the disease through early recognition and treatment of disease. The survey
results from family physicians in one northern state in the U.S. emphasized the need to
increase physician awareness of pertussis being a differential diagnosis in patients with
cold symptoms and/or prolonged cough (Abuhammour, 2008). Increased accurate
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identification of pertussis cases by health care providers can help decrease transmission of
pertussis by treating patients and their contacts accordingly. Interventions that accentuate
the role of health care providers in preventing the spread of pertussis through promotion
of vaccination and patient education may significantly impact public health efforts toward
pertussis prevention (Abuhammour, 2008).

4.6 Collaboration Across Multiple Disciplines
Ten of fourteen studies in this review including data from eleven countries and
three continents, point towards either waning immunity and/or bacterial changes as risk
factors associated with pertussis resurgence. The two risk factors of waning immunity and
bacterial changes may therefore be related in that mutations and adaptations of pertussis
bacteria over time may be linked to the inability of current vaccines to address the correct
pertussis antigen, leading to ineffectiveness of vaccine induced long-term immunity.
Collaboration of multiple disciplines is an important step to addressing pertussis
prevention efforts in highly immunized communities. Clark, T.A., Messonier, N.E, Hadler,
S.C. (2012) states, “It is time for all disciplines of vaccinology- epidemiology, microbiology,
and immunology- to take up challenge of understanding this problem and try to solve it” (p.
21). Continued research efforts into understanding the combined areas of epidemiology of
pertussis reemergence, the biological make-up of current pertussis strains, effectiveness of
vaccines and immunology, and its’ relation to current outbreaks in countries with high
immunization coverage should be encouraged and increased.
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4.7 New Vaccine Development
In efforts to address both the waning immunity of acellular vaccines and emergence
of mutated pertussis bacteria with increased fitness, development of a new pertussis
vaccine should be a significant focus in public health. Clark, T. A., Messonnier, N. E., &
Hadler, S. C. (2012) discuss the importance of pertussis control through development of a
new vaccine and emphasize the focus of this development as “durable immunity and the
ability to interrupt transmission, not just to protect against severe or symptomatic disease”
(p.212).

4.8 Strengths
Strengths of this systematic review include the use of a variety of terms to retrieve
the most expansive list of articles published regarding risk factors associated with
pertussis resurgence. Evaluating published articles in the last ten years allowed for the
most recent and updated studies to be reviewed. Research results and conclusions
obtained between 2004-2014 allowed for a targeting of recent outbreaks, updated data,
and current risk factors focusing on immediate public health interventions and efforts
towards future research strategies. Articles included in this review included studies from
several highly immunized countries in various continents, showing similarities of results in
different regions of the world, especially in regards to bacterial mutations.
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4.9 Limitations
There are various limitations in this systematic review including having only
published articles from PUBMED and EBSCHO included in this review and not grey
literature or other databases. Searches based only in English may have limited data and
associations than those found in studies published in other languages. Limitations may
have occurred in the time frame in which the reviewer conducted the search for this
review. Differing immunization schedules and timing of when the aP vaccine was solely
administered to children and as booster doses, may affect comparison between waning
immunity studies between various highly immunized countries.

4.10 Bias
Bias may have occurred in results found in published articles versus research found
in articles that were not published. Possibility of reviewer bias may have occurred in
regards to the shortened time frame of the literature search and article retrieval and
assessment.
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4.11 Conclusion
● Waning immunity through replacement of whole cell vaccines with acellular vaccines
may be a driving risk factor towards pertussis resurgence
● Bacterial mutations and increased dominance of specific pertussis strains with
increased fitness may be associated with vaccine ineffectiveness leading to pertussis
reemergence
● Inadequate immunization coverage through non-medical exemptions, inadequate
completion of childhood immunization series, and inadequate adult booster dose
immunization coverage may cause increases in pertussis recurrence
● Inadequate provider awareness leading to misdiagnosis and delayed treatment of
infected patients and contacts may contribute to pertussis resurgence
● Promotion of immunization and educational interventions to infants, children,
adolescents, and adults is an important aspect to pertussis transmission control
● Educating healthcare providers on the importance of recognizing pertussis as a
differential diagnosis for patients with symptoms of prolonged cough is a key
component to decreasing the spread of pertussis

● Future research involving collaboration across multiple disciplines is essential to
understanding the risk factors associated with and addressing the resurgence of
pertussis in highly immunized populations
● Future research into novel vaccine development is a significant aspect to protecting
populations from newly emerging dominant pertussis strains
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